LEADER 00802nam0-22002771i-450- 001 990005286190403321 005 20070702112916.0 035 $a000528619 035 $aFED01000528619 035 $a(Aleph)000528619FED01 035 $a000528619 100 $a19990604d1966----km-y0itay50------ba 101 0 $ager 105 $ay-------001yy 200 1 $a<>redaktionsgeschichtliche Methode$eEinfnhrung und Sichtung des Forschungsstandes$fJoachim Rohde 210 $aHamburg$cFurche$d1966 215 $a247 p.$d23 cm 676 $a225.6 700 1$aRohde,$bJoachim$0206105 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990005286190403321 952 $a225.6 ROH 1$bST.REL. 88$fFLFBC 959 $aFLFBC 996 $aRedaktionsgeschichtliche Methode$9537826 997 $aUNINA LEADER 03943nam 2201213z- 450 001 9910557768503321 005 20220111 035 $a(CKB)5400000000045676 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76720 035 $a(oapen)doab76720 035 $a(EXLCZ)995400000000045676 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aRecent Developments in Cancer Systems Biology 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (272 p.) 311 08$a3-0365-1472-4 311 08$a3-0365-1471-6 330 $aThis ebook includes original research articles and reviews to update readers on the state of the art systems approach to not only discover novel diagnostic and prognostic biomarkers for several cancer types, but also evaluate methodologies to map out important genomic signatures. In addition, therapeutic targets and drug repurposing have been emphasized for a variety of cancer types. In particular, new and established researchers who desire to learn about cancer systems biology and why it is possibly the leading front to a personalized medicine approach will enjoy reading this book. 606 $aMedicine and Nursing$2bicssc 610 $aacute myeloid leukemia 610 $abioinformatics 610 $abiomarker 610 $aBoolean model 610 $abrain-tumor-initiating cell (BTIC) 610 $abreast 610 $acancer 610 $acancer genomics 610 $acancer progression 610 $acancer stem cells 610 $acancer systems biology 610 $acirculating miR-1246 610 $aclinical trials 610 $aCNV 610 $acomputational methods 610 $adiagnostic biomarker 610 $adifferential expression 610 $adocking 610 $adrug repurposing 610 $adrug resistance 610 $aElk-1 610 $aEts 610 $aETS 610 $aEts-1 610 $aexperimental model systems 610 $agenomics 610 $aglioma 610 $aglycomics 610 $aglycosaminoglycan binding 610 $aknockdown 610 $alung adenocarcinoma 610 $alung adenocarcinoma (LUAD) 610 $alung cancer 610 $alung squamous cell carcinoma (LUSC) 610 $ametabolomics 610 $ametagenomics 610 $amicroarray 610 $an/a 610 $anetwork 610 $anext-generation sequencing 610 $anon-small-cell lung cancer 610 $aomics 610 $aoptical genome mapping 610 $aovarian 610 $apancreatic cancer 610 $apatient survival 610 $apatient-derived organoids 610 $apatient-derived xenografts 610 $aPEA3 610 $apersonalized medicine 610 $aPI3K-Akt signaling pathways 610 $aprognosis 610 $aprognostic biomarker 610 $aprotein interactome 610 $aproteomics 610 $arenal cancers 610 $arisk group 610 $aSestrin2 610 $asignature 610 $asingle-cell sequencing 610 $aSNV 610 $asolid tumors 610 $astem cell 610 $asurvival 610 $asystems biology 610 $aTargetScan 610 $aTCGA 610 $atranscriptomics 610 $atriple-negative breast cancer 610 $aUBE2C 610 $avirtual screening 615 7$aMedicine and Nursing 700 $aSinha$b Raghu$4edt$01297573 702 $aArga$b Kazim Yalcin$4edt 702 $aSinha$b Raghu$4oth 702 $aArga$b Kazim Yalcin$4oth 906 $aBOOK 912 $a9910557768503321 996 $aRecent Developments in Cancer Systems Biology$93024564 997 $aUNINA